188 related articles for article (PubMed ID: 34715144)
21. Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model.
Liou AT; Liao CC; Chou SF; Chang YS; Chang CS; Shih C
J Biomed Sci; 2019 Nov; 26(1):93. PubMed ID: 31711481
[TBL] [Abstract][Full Text] [Related]
22. Effects and mechanism of Aβ
Zhong M; Wang H; Yan H; Wu S; Wang K; Yang L; Cui B; Wu M; Li Y
Virol J; 2022 Sep; 19(1):151. PubMed ID: 36127711
[TBL] [Abstract][Full Text] [Related]
23. Enterovirus A71 VP1 Variation A289T Decreases the Central Nervous System Infectivity via Attenuation of Interactions between VP1 and Vimentin In Vitro and In Vivo.
Zhu H; Cao Y; Su W; Huang S; Lu W; Zhou Y; Gao J; Zhao W; Zhang B; Wu X
Viruses; 2019 May; 11(5):. PubMed ID: 31121933
[TBL] [Abstract][Full Text] [Related]
24. Mechanism for the lethal effect of enterovirus A71 intracerebral injection in neonatal mice.
Feng M; Liao Y; Gao Y; Jiang G; Wang L; Zhang Y; Fan S; Xu X; Li Q
Lab Invest; 2020 Apr; 100(4):596-605. PubMed ID: 31857694
[TBL] [Abstract][Full Text] [Related]
25. Murine models of neonatal susceptibility to a clinical strain of enterovirus A71.
Xie J; Hu X; Li H; Zhu H; Lin W; Li L; Wang J; Song H; Jia L
Virus Res; 2023 Jan; 324():199038. PubMed ID: 36599394
[TBL] [Abstract][Full Text] [Related]
26. [Establishment of a Model of Infection by Enterovirus 71 in ICR Mice].
Dong Z; Zhang Z; Yang L; Li D; Shi W
Bing Du Xue Bao; 2016 Nov; 32(6):671-82. PubMed ID: 30004196
[TBL] [Abstract][Full Text] [Related]
27. SHFL inhibits enterovirus A71 infection by triggering degradation of viral 3D
Tan C; Qin X; Tan Y; Dong X; Chen D; Liang L; Li J; Niu R; Cao K; He Z; Wei G; Huang M; Zhu X
J Med Virol; 2023 Aug; 95(8):e29030. PubMed ID: 37565734
[TBL] [Abstract][Full Text] [Related]
28. A Mouse Model for Infection with Enterovirus A71 in Small Extracellular Vesicles.
Gu J; Wu J; Cao Y; Zou X; Jia X; Yin Y; Shen L; Fang D; Mao L
mSphere; 2020 Jul; 5(4):. PubMed ID: 32611697
[TBL] [Abstract][Full Text] [Related]
29. Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease.
Lalani S; Gew LT; Poh CL
Peptides; 2021 Feb; 136():170443. PubMed ID: 33171280
[TBL] [Abstract][Full Text] [Related]
30. Global quantitative proteomic analysis profiles of host protein expression in response to enterovirus A71 infection in bronchial epithelial cells based on tandem mass tag (TMT) peptide labeling coupled with LC-MS/MS uncovers the key role of proteasome in virus replication.
Yajie H; Shenglan W; Wei Z; Rufang L; Tingting Y; Yunhui Z; Jie S
Virus Res; 2023 Jun; 330():199118. PubMed ID: 37072100
[TBL] [Abstract][Full Text] [Related]
31. Tribbles pseudokinase 3 promotes enterovirus A71 infection via dual mechanisms.
Wang H; Li K; Cui B; Yan H; Wu S; Wang K; Yang G; Jiang J; Li Y
Emerg Microbes Infect; 2024 Dec; 13(1):2307514. PubMed ID: 38240287
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances in Enterovirus A71 Infection and Antiviral Agents.
Wei Y; Liu H; Hu D; He Q; Yao C; Li H; Hu K; Wang J
Lab Invest; 2024 Feb; 104(2):100298. PubMed ID: 38008182
[TBL] [Abstract][Full Text] [Related]
33. Mouse Scarb2 Modulates EV-A71 Pathogenicity in Neonatal Mice.
Miwatashi W; Ishida M; Takashino A; Kobayashi K; Yamaguchi M; Shitara H; Koike S
J Virol; 2022 Aug; 96(15):e0056122. PubMed ID: 35867561
[TBL] [Abstract][Full Text] [Related]
34. Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence.
Sun L; Tijsma A; Mirabelli C; Baggen J; Wahedi M; Franco D; De Palma A; Leyssen P; Verbeken E; van Kuppeveld FJM; Neyts J; Thibaut HJ
Emerg Microbes Infect; 2019; 8(1):1076-1085. PubMed ID: 31339457
[TBL] [Abstract][Full Text] [Related]
35. An auto-antibody identified from phenotypic directed screening platform shows host immunity against EV-A71 infection.
Cheng YW; Chuang YC; Huang SW; Liu CC; Wang JR
J Biomed Sci; 2022 Feb; 29(1):10. PubMed ID: 35130884
[TBL] [Abstract][Full Text] [Related]
36. Flavonoids as Antiviral Agents for
Lalani S; Poh CL
Viruses; 2020 Feb; 12(2):. PubMed ID: 32041232
[TBL] [Abstract][Full Text] [Related]
37. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
[TBL] [Abstract][Full Text] [Related]
38. Structural and functional analysis of a potent human neutralizing antibody against enterovirus A71.
Chen Z; Bao L; Zhu B; Fu H; Zhu S; Ji T; Xue Y; Liu C; Wang X; Li F; Lv Q; Qi F; Yu P; Deng W; Xu W; Qin C; Liu H; Jin Q
Sci China Life Sci; 2022 Dec; 65(12):2517-2526. PubMed ID: 35696017
[TBL] [Abstract][Full Text] [Related]
39. Enterovirus-A71 exploits RAB11 to recruit chaperones for virus morphogenesis.
Ng QY; Mahendran V; Lim ZQ; Tan JHY; Wong JJF; Chu JJH; Chow VTK; Sze NSK; Alonso S
J Biomed Sci; 2024 Jun; 31(1):65. PubMed ID: 38943128
[TBL] [Abstract][Full Text] [Related]
40. [Analysis on epidemiological characteristics of enterovirus 71 cases of hand-foot-mouth disease based on the active monitoring in Guangdong Province in 2011-2015].
Xie DS; He JF; Yang F; Li H; Kang M; Zhang M; Ye X; Tan XH; Ni XH; Hu L; Sun LM
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):738-742. PubMed ID: 29996302
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
